An international phase III clinical trial (SOLO-2 trial) revealed that maintenance therapy with the PARP inhibitor Ola demonstrated a significant extension of progression-free survival (PFS) compared to placebo in patients with platinum-sensitive recurrent ovarian cancer with germline BRCA1/2 variants [7]. This evidence concerns the gene BRCA1 and ovarian carcinoma.